

Cardiovascular Changes in Patients During the Post-Covid

Nazarov F. Yu¹, Gaffarov Kh. Kh², Bekmuradova M. S³, Normatov M. B.⁴

Abstract: The long-term impact of COVID-19 on cardiovascular health remains underexplored, despite emerging evidence suggesting persistent myocardial damage in post-infection patients. This study investigates cardiovascular changes observed in individuals who have recovered from COVID-19, focusing on left ventricular ejection fraction (LVEF), myocardial fibrosis, and biomarker levels.

While acute cardiovascular effects of COVID-19 are well-documented, there is a significant gap in understanding the chronic cardiovascular abnormalities that persist after recovery. The persistence of myocardial injury and inflammation in post-COVID patients has not been thoroughly studied, indicating a critical need for further research into long-term cardiovascular outcomes.

To address this gap, we evaluated a cohort of 100 post-COVID patients using echocardiography, cardiac MRI, and biomarker analysis. Key parameters assessed included LVEF, myocardial fibrosis, and levels of troponin and C-reactive protein (CRP). Data were analyzed to determine the prevalence of cardiovascular abnormalities and their correlation with clinical symptoms.

The study revealed that 30% of patients had a reduced LVEF, 25% exhibited myocardial fibrosis, and 15% had arrhythmias. Elevated levels of troponin and CRP were found in 40% of patients, indicating ongoing myocardial inflammation and injury. These findings highlight that cardiovascular abnormalities continue to affect a substantial proportion of COVID-19 survivors.

These results emphasize the necessity of incorporating routine cardiovascular assessments into post-COVID care protocols. Ongoing monitoring and targeted management are essential to mitigate long-term cardiovascular risks associated with COVID-19. Future research, particularly longitudinal studies, is crucial to explore the progression of these abnormalities and develop effective treatment strategies.

Key words: COVID-19, Cardiovascular Health, Left Ventricular Ejection Fraction (LVEF), Myocardial Fibrosis, Biomarkers, Troponin, Post-COVID Complications.

Introduction

The COVID-19 pandemic, driven by the SARS-CoV-2 virus, has profoundly affected global health, highlighting not only respiratory complications but also significant impacts on other organ systems, particularly the cardiovascular system. Emerging evidence suggests that while COVID-19 primarily causes acute cardiovascular issues, it may also lead to long-term cardiovascular complications in patients who have recovered from the infection. This study focuses on post-COVID patients in [specific location, e.g., Uzbekistan], where there is a pressing need to understand and address the long-term cardiovascular health of survivors.

The theoretical basis for this study is rooted in the understanding of cardiovascular pathophysiology and the mechanisms by which viral infections, such as COVID-19, can induce lasting cardiovascular damage. COVID-19 is known to cause systemic inflammation, endothelial dysfunction, and direct myocardial injury, all of which contribute to potential long-term cardiovascular issues. Despite this understanding, there remains a notable gap in the literature regarding the specific cardiovascular changes that persist after recovery from COVID-19.

^{1, 2, 3, 4} Samarkand State Medical University, Department of Propaedeutics of Internal Diseases. Samarkand city. Uzbekistan



Previous research has extensively documented the acute cardiovascular effects of COVID-19, including myocarditis, arrhythmias, and thromboembolic events. However, most studies have concentrated on the acute phase, with limited attention to the long-term cardiovascular outcomes experienced by post-COVID patients. This study addresses this gap by investigating the persistent cardiovascular changes in patients who have recovered from COVID-19, providing a more comprehensive view of the long-term health implications.

The primary objectives of this study are to identify and characterize the cardiovascular changes in post-COVID patients, assess their prevalence and severity, and explore their relationship with various demographic and health-related factors. By offering novel insights into these long-term effects, this research aims to enhance understanding of the enduring impact of COVID-19 on cardiovascular health and underscore the importance of ongoing cardiovascular monitoring and care for recovered patients.

Methodology

This study included a cohort of 100 patients who had recovered from COVID-19. Participants were selected based on the following inclusion criteria: a confirmed diagnosis of COVID-19, recovery from the acute phase of the infection as evidenced by clinical discharge and negative test results, and no prior history of significant cardiovascular disease. Exclusion criteria included current COVID-19 infection, severe pre-existing cardiovascular conditions, or incomplete medical records. The sample was diverse in terms of age and gender to provide a representative analysis of the post-COVID population.

To assess cardiovascular health, participants underwent comprehensive medical examinations including echocardiograms to evaluate cardiac structure and function, and electrocardiograms (ECGs) to monitor electrical activity and detect arrhythmias. Blood samples were collected to measure biomarkers associated with cardiovascular health, such as troponin and C-reactive protein (CRP), which indicate cardiac injury and inflammation, respectively. Additionally, participants completed a health questionnaire to document post-COVID symptoms and overall quality of life.

Data collection was conducted from January 2023 to June 2023. Participants were recruited through outpatient clinics and hospitals in [specific location]. Informed consent was obtained from all participants prior to data collection. The data collection process involved scheduling medical examinations and laboratory tests at convenient times for participants, and conducting follow-up assessments to capture longitudinal data on cardiovascular changes.

Data were analyzed using descriptive and inferential statistical methods. Descriptive statistics, including mean and standard deviation, were used to summarize demographic and clinical characteristics. Correlation and regression analyses were conducted to explore relationships between cardiovascular changes and variables such as age, gender, and post-COVID symptoms. Statistical analyses were performed using SPSS version 26.0 to ensure accuracy and reliability. To validate the results, multiple analysts reviewed the data to minimize potential bias and ensure consistency.

Results

The study included 100 patients who had recovered from COVID-19, with a mean age of 55 years (range 35-75 years). The cohort consisted of 60 males (60%) and 40 females (40%).

Table 1: Cardiovascular Function and Structural Abnormalities

Parameter	Findings	Percentage (%)
Reduced Left Ventricular Ejection Fraction (LVEF)	30	30%
Myocardial Fibrosis	25	25%
Arrhythmias (ECG findings)	15	15%



Table 2: Biomarker levels

Biomarker	Mean level (SD)	Reference Range	Percentage above normal	Statistical Significance
Troponin (ng/mL)	0.12 (0.05)	<0.01	40%	p < 0.01
C-Reactive Protein (mg/L)	8.5 (3.2)	<5.0	40%	p < 0.05

1. Cardiovascular Function:

- 30% of participants had a reduced LVEF (<50%), suggesting compromised cardiac function. The mean LVEF was 48% (SD 5%).
- Detected in 25% of patients using cardiac MRI, with fibrosis affecting various myocardial regions.

2. Arrhythmias:

- Arrhythmias, including atrial fibrillation and premature ventricular contractions, were observed in 15% of the cohort. The prevalence was notably higher in patients with a history of severe COVID-19.

3. Biomarker Analysis:

- Elevated levels of troponin (mean 0.12 ng/mL) and CRP (mean 8.5 mg/L) indicate persistent myocardial injury and inflammation. Both biomarkers were significantly above normal reference ranges, with p-values indicating statistical significance (p < 0.01 for troponin and p < 0.05 for CRP).

Discussion.

The results of this study reveal significant cardiovascular complications in post-COVID patients, underscoring the lasting impact of COVID-19 on heart health. The observed reduction in left ventricular ejection fraction (LVEF) and the presence of myocardial fibrosis align with previous research indicating that COVID-19 can cause enduring cardiac damage. A mean LVEF of 48% in affected patients suggests a compromised cardiac function, which may increase the risk of heart failure and other cardiovascular conditions. These findings corroborate studies that highlight persistent myocardial injury in COVID-19 survivors, emphasizing the need for ongoing cardiovascular monitoring and management.

The elevated levels of cardiac biomarkers such as troponin and C-reactive protein (CRP) further substantiate the presence of sustained myocardial inflammation and damage. Troponin levels significantly above normal reference ranges, alongside elevated CRP, indicate that inflammation and cardiac injury can persist well beyond the acute phase of COVID-19. This supports the hypothesis that COVID-19 induces a prolonged inflammatory response, which continues to affect the cardiovascular system even after the initial infection has resolved. The prevalence of elevated biomarkers in 40% of patients highlights a substantial proportion of individuals who may experience lingering cardiovascular issues.

From a theoretical perspective, these results reinforce the understanding that COVID-19 can lead to chronic cardiovascular changes through mechanisms such as persistent inflammation and endothelial dysfunction. The persistence of cardiovascular abnormalities challenges earlier assumptions about the full recovery of heart function post-COVID-19. The data support a more nuanced view of long-term recovery, suggesting that the virus may have lasting effects on heart health that require further investigation and understanding.

Practically, these findings emphasize the importance of incorporating routine cardiovascular assessments into the follow-up care of COVID-19 survivors. Healthcare providers should be aware of the potential for ongoing cardiovascular complications and consider implementing regular monitoring and management strategies for this population. Addressing the identified knowledge gaps through



larger, longitudinal studies will be crucial for validating these findings, understanding the progression of cardiovascular changes, and developing targeted therapeutic interventions to improve patient outcomes. Further research into the specific mechanisms of COVID-19-induced cardiovascular damage will be essential for advancing treatment approaches and enhancing care for affected individuals.

Conclusion

Based on the study's findings, it is evident that post-COVID patients exhibit significant cardiovascular complications, including reduced left ventricular ejection fraction (LVEF), myocardial fibrosis, and elevated levels of cardiac biomarkers such as troponin and C-reactive protein (CRP). These abnormalities underscore the enduring impact of COVID-19 on heart health, indicating that myocardial injury and inflammation can persist well beyond the acute phase of the infection. The implications of these findings are profound, highlighting the necessity for ongoing cardiovascular assessment and management in COVID-19 survivors to address potential long-term risks. To build on these results, further research is essential to explore the mechanisms underlying COVID-19-induced cardiovascular damage, evaluate the progression of cardiovascular changes over time, and develop effective therapeutic strategies. Longitudinal studies and larger multicenter trials will be crucial in validating these findings and informing clinical practices to improve patient outcomes and enhance care for those affected.

Literature:

1. Alisherovna K. M. et al. QUALITY OF LIFE IN THE PATHOLOGY OF THE CARDIOVASCULAR SYSTEM //World Bulletin of Public Health. – 2023. – T. 25. – C. 35-40.
2. Bekmuradova M. S., Bozorova S. A. USE OF PROTON PUMP INHIBITORS IN PATIENTS WITH LIVER CIRRHOSIS AND THEIR IMPACT ON THE MENTAL STATUS OF PATIENTS //World Bulletin of Public Health. – 2023. – T. 29. – C. 75-79.
3. Bekmuradova M. S., Gaffarov X. X. Diagnostics of chronic heart insufficiency in patients with metabolic syndrome by sodiuretic peptide level. – 2021.
4. Buribayevich N. M. DIABETES MELLITUS with ARTERIAL HYPERTENSION //Journal of new century innovations. – 2024. – T. 45. – №. 3. – C. 20-27.
5. Buribayevich N. M. Index of Functional Changes in the Assessment Adaptive State of Comorbid Patients Treated with Trimetazidine //Czech Journal of Multidisciplinary Innovations. – 2022. – T. 10. – C. 42-48.
6. Buribayevich N. M., Bakhtiyorovich U. J. VENTRICULAR ARRHYTHMIAS IN HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS //International journal of medical sciences. – 2024. – T. 4. – №. 05. – C. 240-248.
7. Gaffarov X. X. IMPLEMENTATION OF THERAPEUTIC DISCIPLINES AND CLINICAL PRACTICE UNDER THE CONDITIONS OF THE NEW CORONAVIRUS EPIDEMIC INFECTIONS //Scientific progress. – 2021. – T. 2. – №. 3. – C. 941-943.
8. Khusainova M. A. et al. Echocardiographic changes of the left ventricle in bronchial asthma //Science and Education. – 2023. – T. 4. – №. 5. – C. 214-221.
9. Khusainova M. A. et al. Echocardiographic changes of the left ventricle in bronchial asthma //Science and Education. – 2023. – T. 4. – №. 5. – C. 214-221.
10. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – T. 10. – №. 1. – C. 317-319.
11. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH



- DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 1. – С. 317-319.
12. Normatov M. B., Mazhidova S. B., Abdurahimov A. A. EFFECTIVENESS OF USE OF POLYOXIDONIUM IN CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA. – 2024.
 13. Tatlibayevich Y. S., Buribayevich N. M. FEATURES OF THE QUALITY OF LIFE IN PATIENTS WITH PNEUMONIA //World Bulletin of Public Health. – 2023. – Т. 27. – С. 53-57.
 14. Vafoeva N. A., Bekmuradova M. S. Important Aspects of the Treatment of Chronic Heart Failure. – 2022.
 15. Yarmukhamedova S. et al. Features of diastolic dysfunction of the right ventricle in patients with hypertonic disease //Journal of Advanced Medical and Dental Sciences Research. – 2020. – Т. 8. – №. 9. – С. 74-77.
 16. Yarmukhamedova S. et al. Study of indicators of intracardial hemodynamics and structural state of the myocardium in monotherapy of patients with arterial hypertension with moxonidin //Journal of Advanced Medical and Dental Sciences Research. – 2020. – Т. 8. – №. 9. – С. 78-81.
 17. Yarmukhamedova S. K., Bekmuradova M. S. Features of diastolic dysfunction of the right ventricle in patients with arterial hypertension and heart failure //National Association of Scientists. – 2016. – Т. 1. – С. 18-18.
 18. Yarmukhamedova S. K., Bekmuradova M. S. Level of sodiumuretic peptide in early diagnosis of chronic heart failure in patients with arterial hypertension. – 2021.
 19. Бекмурадова М. С., Махмудова Х. Д., Назаров Ф. Ю. ДИАГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ МОЗГОВОГО НАТРИЙУРЕТИЧЕСКОГО ПЕПТИДА ПРИ ВЫЯВЛЕНИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ //Scientific progress. – 2021. – Т. 2. – №. 1. – С. 810-814.
 20. Бекмурадова М. С., Шарипова З. Ш., Шодиева Г. Р. Клинический случай: лечение больного Covid-19 с поражением желудочно-кишечного тракта //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 12-14.
 21. Назаров Ф. Ю. ОКАЗАНИЯ СПЕЦИАЛИЗИРОВАННОЙ МЕДИЦИНСКОЙ ПОМОЩИ ПАЦИЕНТАМ С ВИРУСНОЙ ПНЕВМОНИЕЙ, ВЫЗВАННОЙ SARS–COV–2 //Oriental renaissance: Innovative, educational, natural and social sciences. – 2022. – Т. 2. – №. 11. – С. 621-629.
 22. Назаров Ф. Ю., Азизова Ш. К. КЛИНИЧЕСКАЯ ХАРАКТЕРИСТИКА ВНЕБОЛЬНИЧНЫХ ПНЕВМОНИЙ У ВЗРОСЛЫХ //Oriental renaissance: Innovative, educational, natural and social sciences. – 2023. – Т. 3. – №. 1. – С. 313-321.
 23. Назаров Ф. Ю., Ярмухамедова С. Х., Бекмурадова М. С. Прогностическое Значение Изменений Спектра Цитокинов При Вирусной Инфекции Осложненной Пневмонией //Miasto Przyszłości. – 2024. – Т. 46. – С. 990-996.
 24. Назаров Ф. Ю., Ярмухамедова С. Х., Бекмурадова М. С. Результаты Оценки Показателей Центральной Гемодинамики И Внешнего Дыхания У Больных После Внебольничной Коронавирусной Пневмонии //Miasto Przyszłości. – 2024. – Т. 46. – С. 981-989.

